A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
I-Mab Biopharma US Limited
Start Date
June 29, 2022
End Date
June 28, 2023
Administered By
Duke Cancer Institute
Awarded By
I-Mab Biopharma US Limited
Start Date
June 29, 2022
End Date
June 28, 2023